At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 55 enrolled
Drug / intervention
Berberine plus danazoldrug
Likely dose
Berberine plus danazol 0.3gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Combination of Danazole With Berberine in the Treatment of ITP
In Brief
A Phase 2 clinical trial evaluating Berberine plus danazol for Corticosteroid-resistant or Relapsed ITP. Targeting 55 participants across 1 site.
Detailed Summary
A prospective, multicenter, open-label, Phase II, single arm, trial performed in 6 departments of hematology in China
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorticosteroid-resistant or Relapsed ITP
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
20162017201820192020202120222023202420252026
Enrollment StartJan 2016
First PostedApr 2019
Primary CompletionDec 2020
Study CompletionJun 2021
TodayJul 2026
First PostedApr 10, 2019
Enrollment StartJan 20, 2016
Primary CompletionDec 30, 2020
Study CompletionJun 30, 2021
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 7.2 years ago
Interventions
Berberine plus danazoldrug
Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks